Currently the medicinal chemistry of DV is in its infancy, with many targets and new lead compounds being identified with increasing frequency. This review examines the information currently available on DV inhibitors and potential targets for therapeutic invention. However, because of the diverse, scattered, and relatively limited information available, lead compounds possessing relatively weak activity have also been included here. In addition, although significant information can be reported in patents, they rarely specify exact structures of their best inhibitors and commonly describe a vast array of compounds utilizing a central skeleton. Many patents claiming molecules with activity against dengue do not actually present this inhibitory data with WNV inhibitory activities more commonly stated. Here we have confined ourselves to reporting data from patents that specifically state they are active against DV (cf. with the more general flavivirus or WNV activity) even if only general structure scaffolds are defined. With this approach, we aim to present a currently complete picture of the medicinal chemistry of DV to allow the rapid development of chemotherapeutics.